



**Journal of Hospital Pharmacy**  
**An Official Publication of Bureau for Health & Education Status Upliftment**  
(Constitutionally Entitled as Health-Education, Bureau)

**Study of Efficacy and Tolerability of Atorvastatin Alone or in Combination with Fenofibrate in Hyperlipidemia Patients with and without Type II Diabetes Mellitus in Tertiary Care Hospital**

*\* Dr. K. Jagadeesh<sup>1</sup>, Jampula Hemalatha<sup>2</sup> Kakarla Mahesh<sup>3</sup>, Dr. Y. Naveen<sup>4</sup>*

<sup>\*1</sup> Pharm.D, Assistant professor, Department of Pharmacy practice, St.Johns College of Pharmaceutical sciences, yemmiganur-518360, Kurnool (District), Andhra Pradesh, India.

<sup>2</sup>Pharm.D Intern, Department of Pharmacy practice, St.Johns College of Pharmaceutical sciences, yemmiganur-518360, Kurnool (District), Andhra Pradesh, India.

<sup>3</sup> Pharm.D Intern, Department of Pharmacy practice, St.Johns College of Pharmaceutical sciences, yemmiganur-518360, Kurnool (District), Andhra Pradesh, India.

<sup>4</sup>MBBS, MD, Department of General medicine, Sree shakthi nursing home, yemmiganur-518360, Kurnool (District), Andhra Pradesh, India.

**Running Title:** Efficacy and tolerability of atorvastatin alone or in combination with fenofibrate in hyperlipidemia patients with and without type ii diabetes mellitus in tertiary care hospital.

**Email Id:** [serviceheb@gmail.com](mailto:serviceheb@gmail.com)

#### ABSTRACT


**Purpose:** This study evaluated the effect and tolerability of Atorvastatin – Fenofibrate combination on lipid profile in comparison to Atorvastatin alone in patients with Hyperlipidemia with and without Type 2 Diabetes mellitus.

**Methods:** This prospective, parallel, comparative study includes total 99 Hyperlipidemia patients with and without Type 2 Diabetes mellitus, studied for a period of 6 months. These patients were randomly assigned to atorvastatin(10 mg/day, n = 49), and combination of both(Atorvastatin 10 mg/day + Fenofibrate 160 mg/day, n = 50).

**Results:** By assessing the efficacy of both therapies in Hyperlipidemia with Type 2 Diabetes mellitus patients, percentage decrease in parameters like, TC, TG and RBC were 14%,16%, and 18% in Atorvastatin group as compared to 22%,32%, and 29% in Atorvastatin+Fenofibrate group. The increase in HDL-C level was 17% in Atorvastatin+Fenofibrate group as compared to 12% in Atorvastatin group. Where as in only Hyperlipidemia without Type 2 Diabetes mellitus patients, the percentage decrease in parameters like, TC, and TG were,13%, and 14%, in Atorvastatin group compared to 25% and 28%, in Atorvastatin+Fenofibrate group. The increase in HDL-C level was 19% in Atorvastatin+Fenofibrate group as compared to 12% in Atorvastatin group and the increase in RBS was 3% in Atorvastatin group as compared to 4% in Atorvastatin+Fenofibrate.

**Conclusion:** The efficacy of percentage decrease lipid parameters was slightly better treated with combination therapy than compare to monotherapy in Type 2 Diabetes mellitus patients. Both monotherapy and combination therapy were safe and well tolerated.

**Keywords:** Hyperlipidemia, Type II Diabetes mellitus, Atorvastatin, Fenofibrat

Access this Article Online	Quick Response Code 
Website: <a href="http://www.journalofhospitalpharmacy.in">http://www.journalofhospitalpharmacy.in</a>	
Received on 23/03/2023	
Accepted on 01/04/2023 © HEB All rights reserved	